JO
LEXX icon

John Overdeck’s Lexaria Bioscience LEXX Stock Holding History

John Overdeck’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-871
Closed -$32K – 2950
2022
Q3 		$32K Sell
871
-289
-25% -$12.3K ﹤0.01% 2351
2022
Q2 		$52K Buy
+1,160
New +$46.6K ﹤0.01% 2342

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $199B AUM 37.98% 1-Year Est. Return

John Overdeck's LEXX Position: Q4 2022 in Review

John Overdeck sold out of Lexaria Bioscience (LEXX) in Q4 2022, closing a stake of 871 shares — an estimated $32K sold.

John Overdeck first reported a position in LEXX in Q2 2022 and held it in 2 quarters. The position peaked at $52K in Q2 2022. 16 funds tracked by Wall St. Rank hold LEXX as of Q4 2022.

  • John Overdeck reported no remaining Lexaria Bioscience position as of Q4 2022 after selling out during the quarter.
  • John Overdeck sold 871 Lexaria Bioscience shares in Q4 2022, an estimated $32K.
  • John Overdeck first reported a position in Lexaria Bioscience in Q2 2022 and held it in 2 quarters.
  • John Overdeck's Lexaria Bioscience position peaked at $52K in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q4 2022.

Based on Two Sigma Investments's 13F filing for Q4 2022, filed 14 Feb 2023.